Bank Of New York Mellon Corp Checkpoint Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	BUY	$2.5 - $3.53 $61,177 - $86,382	24,471 Added 137.1%	42,320 $140,000
Q2 2021 Aug 11, 2021	SELL	$2.36 - $3.2 $242,409 - $328,691	-102,716 Reduced 85.2%	17,849 $52,000
Q1 2021 May 13, 2021	BUY	$2.6 - $4.16 $2,095 - $3,352	806 Added 0.67%	120,565 $378,000
Q4 2020 Feb 09, 2021	BUY	$2.19 - $2.96 $25,877 - $34,975	11,816 Added 10.95%	119,759 $317,000
Q3 2020 Nov 12, 2020	BUY	$1.62 - $4.24 $27,893 - $73,004	17,218 Added 18.98%	107,943 $289,000
Q2 2020 Aug 12, 2020	BUY	$1.19 - $2.27 $41,960 - $80,042	35,261 Added 63.57%	90,725 $179,000
Q1 2020 May 06, 2020	BUY	$1.11 - $2.43 $11,810 - $25,855	10,640 Added 23.74%	55,464 $83,000
Q4 2019 Feb 14, 2020	SELL	$1.18 - $2.39 $22,738 - $46,055	-19,270 Reduced 30.07%	44,824 $77,000
Q3 2019 Nov 07, 2019	BUY	$2.15 - $3.36 $9,855 - $15,402	4,584 Added 7.7%	64,094 $159,000
Q2 2019 Aug 12, 2019	BUY	$2.75 - $5.0 $104,051 - $189,185	37,837 Added 174.58%	59,510 $181,000
Q1 2019 May 14, 2019	BUY	$2.01 - $4.01 $3,358 - $6,700	1,671 Added 8.35%	21,673 $62,000
Q4 2018 Feb 11, 2019	BUY	$1.54 - $3.35 $30,803 - $67,006	20,002 New	20,002 $36,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $297M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.